CTMX News and Press, CytomX Therapeutics Inc. From 05/08/24

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY ® ADC, in solid tumors. Initial data anticipated in...

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 pat...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-05-07 16:52:00 ET More on CytomX CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript Cyt...

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combina...

2024-05-06 12:41:30 ET More on CytomX CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript Cyt...

2024-05-06 00:00:04 ET Roger Song from Jefferies issued a price target of $8.00 for CTMX on 2024-05-05 19:42:00. The adjusted price target was set to $8.00. At the time of the announcement, CTMX was trading at $4.455. The overall price target consensus is at $5.63 with h...

2024-05-03 08:29:21 ET More on premarkets gainers & stock Zura Bio stock jumps on plans to raise $112.5M in private financing Financial information for Binah Capital Group, Inc. Financial information for Healthcare Triangle Seeking Alpha’s Quant Ra...

2024-05-02 15:32:05 ET Summary CytomX Therapeutics, Inc. results from phase 1a dose-escalation study, using CX-904 for the treatment of patients with EGFR expressing solid tumors, expected with Q1 2024 earnings on May 8, 2024. Pending positive data, plus at the discretion of partn...

2024-05-02 10:03:17 ET Summary BioAtla is a biotech company focused on developing conditionally activated biologics for cancer therapy. Their approach is an attempt to harness the Warburg effect to conditionally activate immunological molecules. BioAtla has promising pipeline ...